MedTrace Logo

Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion

NCT00103766 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2006-08-01

No results posted yet for this study

Summary

The purpose of this study is to assess the benefit to patients with empyema or complicated parapneumonic effusion (CPE) using a daily versus twice daily Alteplase regimen of two different dose strategies compared with saline placebo.

Conditions

  • Empyema
  • Pleural Effusion

Interventions

DRUG

Alteplase

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Scott and White Hospital & Clinic

    collaborator OTHER

  • Scott, Sherwood and Brindley Foundation

    collaborator OTHER

  • Texas A&M University

    collaborator OTHER

  • O'Brien, Jeana D., MD, FACP, FCCP

    lead INDIV

Principal Investigators

  • Jeana D O'Brien, MD, FACP, FCCP · Scott and White Memorial Hospital and Scott, Sherwood and Brindley Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00103766 on ClinicalTrials.gov